Zobrazeno 1 - 10
of 599
pro vyhledávání: '"S. Wierzbicki"'
Publikováno v:
Archives of Civil Engineering, Vol Vol. 66, Iss No 2, Pp 147-164 (2020)
The paper presents a method of structural monitoring with the use of angular displacement measurements performed with inclinometer devices. Inclinometer method is a solution free from the basic disadvantages of optical methods used commonly in struct
Externí odkaz:
https://doaj.org/article/7d61543d1e8a4962bd8f7f0d91560340
Autor:
Alan Jones, Katherine Peers, Anthony S. Wierzbicki, Radha Ramachandran, Michael Mansfield, Charlotte Dawson, Antonio Ochoa-Ferraro, Handrean Soran, Fiona Jenkinson, Ian McDowell, Paul Downie, Paul Hamilton, Richard D Jones
Publikováno v:
Atherosclerosis. 375:67-74
Autor:
Joe Kai, Nadeem Qureshi, Stephen F Weng, Folkert W Asselbergs, Anthony S Wierzbicki, Riyaz S Patel, Ralph K Akyea, Jo Leonardi-Bee, Paul Durrington, Oluwaseun H Ibiwoye
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. With advances in early diagnosis and treatment of CVD and increasing life expectancy, more people are surviving initial CVD events. However, models fo
Externí odkaz:
https://doaj.org/article/2ebf619f5cfc4a7b9d92afc7b9fb7ec0
Autor:
Eun Ji Kim, Anthony S. Wierzbicki
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 11 (2020)
A consensus has formed based on epidemiological studies and clinical trials that intervention to reduce low density lipoprotein cholesterol (LDL-C) will reduce cardiovascular disease (CVD) events. This has progressively reduced the thresholds for int
Externí odkaz:
https://doaj.org/article/806fa9680b684e228145e11ddb072984
Publikováno v:
Expert Opinion on Pharmacotherapy. 23:1363-1370
Low density Lipoprotein cholesterol)LDL-C) levels show a clear relationship with cardiovascular disease (CVD). Statins are first line agents to reduce LDL-C and CVD risk. However, combination lipid-lowering therapy is often required to achieve large
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-9 (2017)
Abstract Background Lipoprotein lipase deficiency (LPLD) is an autosomal recessive inherited disorder caused by loss-of-function mutations in genes involved in the lipoprotein lipase pathway. It is characterised by chylomicronaemia, severe hypertrigl
Externí odkaz:
https://doaj.org/article/e29595ab223a4fcdb22c6f285b811407
Publikováno v:
Current Opinion in Endocrinology, Diabetes & Obesity. 29:124-130
Multiple studies have shown a strong association between lipids and diabetes. These are usually described through the effects of cholesterol content of lipid particles and in particular low-density lipoprotein. However, lipoprotein particles contain
Publikováno v:
Vascular Health and Risk Management
Lipoprotein(a) forms a subfraction of the lipid profile and is characterized by the addition of apolipprotein(a) (apo(a)) to apoB100 derived particles. Its levels are mostly genetically determined inversely related to the number of protein domain (kr
Autor:
Bilal Bashir, Jan H. Ho, Paul Downie, Paul Hamilton, Gordon Ferns, Dev Datta, Jaimini Cegla, Anthony S. Wierzbicki, Charlotte Dawson, Fiona Jenkinson, Hannah Delaney, Michael Mansfield, Yee Teoh, Zosia Miedzybrodzka, Haya Haso, Paul N. Durrington, Handrean Soran
Publikováno v:
Bashir, B, Ho, J, Downie, P, Hamilton, P, Ferns, G, Datta, D, Cegla, J, Wierzbicki, A, Dawson, C, Jenkinson, F, Delaney, H, Mansfield, M, Teoh, Y, Miedzybrodzka, Z, Haso, H, Durrington, P & Soran, H 2023, ' Severe hypertriglyceridaemia and chylomicronaemia syndrome—causes, clinical presentation, and therapeutic options ', Metabolites, vol. 13, no. 5, pp. 621 . https://doi.org/10.3390/metabo13050621
We have reviewed the genetic basis of chylomicronaemia, the difference between monogenic and polygenic hypertriglyceridaemia, its effects on pancreatic, cardiovascular, and microvascular complications, and current and potential future pharmacotherapi
Publikováno v:
Current Opinion in Cardiology. 36:469-477
Purpose of review Triglycerides (TGs) are measured as part of routine lipid profiles but their relationship to cardiovascular disease (CVD) risk has been controversial and overshadowed by high-density lipoprotein cholesterol (HDL-C). Recent findings